Clinical value of human epididymis protein 4 and the Risk of Ovarian Malignancy Algorithm in differentiating borderline pelvic tumors from epithelial ovarian cancer in early stages

摘要: Abstract Objective The clinical value of human epididymis protein 4 (HE4) and the possibility its use in differential diagnosis patients with benign, borderline epithelial ovarian cancer early International Federation Gynaecology Obstetrics (FIGO) stages. Study design study group consisted 205 women, including 60 cancer, 18 tumors, 77 benign lesions 50 healthy subjects. In all patients, before treatment control groups, we determined CA 125 HE4 serum by electrochemiluminescence on basis COBAS e601 system. For comparison two independent used U Mann–Whitney test. analysis diagnostic power assessed parameters has been using MedCalc statistical program. probability disease free survival (DFS) was evaluated log-rank test Cox regression model. Results Concentrations HE4, Risk Ovarian Malignancy Algorithm (ROMA) were significantly higher than ( P Conclusions Determination concentrations a significant value, especially elevated levels. combined assessment ROMA algorithm is helpful differentiating tumors pelvic from FIGO not lesions.